Talis Biomedical Stock (NASDAQ:TLIS)
Previous Close
$1.56
52W Range
$1.37 - $9.60
50D Avg
$5.95
200D Avg
$7.82
Market Cap
$2.86M
Avg Vol (3M)
$28.14K
Beta
1.62
Div Yield
-
TLIS Company Profile
Talis Biomedical Corporation operates as a molecular diagnostic company. The company is developing the Talis One system to address limitations of existing point-of-care diagnostic testing technologies for infectious diseases. It also offers Talis One COVID-19 Test System, which focuses on detection of SARS-CoV-2, the virus that causes COVID-19. In addition, it develops Talis One assay kit for respiratory infections, infections related to women's health, and sexually transmitted infections; and other tests for the detection of other respiratory infections, such as a respiratory panel test to detect influenza A, influenza B, and respiratory syncytial virus. Talis Biomedical Corporation was incorporated in 2013 and is headquartered in Menlo Park, California.
TLIS Performance
Peer Comparison
| Ticker | Company |
|---|---|
| INVO | INVO Bioscience, Inc. |
| SGHT | Sight Sciences, Inc. |
| SSKN | STRATA Skin Sciences, Inc. |
| TIVC | Tivic Health Systems, Inc. |
| VAPO | Vapotherm, Inc. |
| NUWE | Nuwellis, Inc. |
| NPCE | NeuroPace, Inc. |
| BVS | Bioventus Inc. |
| BBLG | Bone Biologics Corporation |
| BJDX | Bluejay Diagnostics, Inc. |
| HSCS | Heart Test Laboratories, Inc. |
| MOTS | Motus GI Holdings, Inc. |
| TNON | Tenon Medical, Inc. |